Please login to the form below

Not currently logged in
Email:
Password:

inflammatory disease

This page shows the latest inflammatory disease news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws EU filing for canakinumab

Novartis withdraws EU filing for canakinumab

The decision is a further setback for this expansion in the use of canakinumab, which Novartis already markets as an inflammatory disease treatment under the brand name Ilaris.

Latest news

  • BMS to test Vedanta’s bacterial therapy with Opdivo BMS to test Vedanta’s bacterial therapy with Opdivo

    The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... or faecal microbiota transplants – which it claims don’t tackle the underlying

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Inflammation is considered to be a trigger for the liver damage that characterises the disease. ... Feldstein – sits apart from rival therapies and could have applications beyond NASH in other inflammatory disorders gout including inflammatory bowel

  • NHS says Humira biosimilar deal will save £300m NHS says Humira biosimilar deal will save £300m

    Humira (adalimumab) is a TNF blocker used to treat inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease, and is currently the world’s top-selling medicine, adding more

  • Google boosts healthcare business with new hire Google boosts healthcare business with new hire

    Earlier this year, Google’s life science and healthcare division Verily teamed up with Gilead to develop a high-res molecular map of inflammatory diseases. ... This allows identification and characterisation of inflammatory disease mechanisms. Verily

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    presence than BMS in the inflammatory disease market. ... BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.

More from news
Approximately 1 fully matching, plus 141 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis, ... ulcerative colitis, type 1

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD).  . ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... inflammatory bowel disease and multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics